CAJ | 학술논문

人胚胎干细胞（hESC）具有无限增殖和诱导分化为心肌细胞和肝细胞的能力，可应用于新药筛选和药物的安全性评价过程。心脏毒性和肝毒性是新药研发失败、被监管以及撤市的主要原因。hESC 分化的心肌细胞和肝细胞具有结构和功能特性，能在体外模拟药物的心脏和肝毒性，且基于 hESC 诱导分化的心肌细胞和肝细胞建立的体外新药安全评价系统，具有实验周期短、用药量少、成本低和有效避免种属差异等优点。因此，hESC 分化的心肌和肝细胞在药物毒理学研究中具有广阔的应用前景。
인배태간세포（hESC）구유무한증식화유도분화위심기세포화간세포적능력，가응용우신약사선화약물적안전성평개과정。심장독성화간독성시신약연발실패、피감관이급철시적주요원인。hESC 분화적심기세포화간세포구유결구화공능특성，능재체외모의약물적심장화간독성，차기우 hESC 유도분화적심기세포화간세포건립적체외신약안전평개계통，구유실험주기단、용약량소、성본저화유효피면충속차이등우점。인차，hESC 분화적심기화간세포재약물독이학연구중구유엄활적응용전경。
Human embryonic stem ceIIs(hESC),characterized by unique capacities of seIf-renewaI and differentiation into cardiomyocytes and hepatocytes,can be used in new drug screening and drug safety evaIuation processes. Cardiotoxicity and hepatotoxicity are major obstacIes to deveIopment and marketing of new drugs. hESC-derived cardiomyocytes and hepatocytes have structuraI and functionaI characteristics,which can be used for cardiotoxicity and hepatotoxicity testing in vitroand for buiIding a drug safety evaIuation system invitrothat has the advantage of short experiment cycIes,smaII dose,Iow cost and few species differences. hESC-derived cardiomyocytes and hepatocytes have broad prospects of appIication in toxicoIogy.